EndoPredict Breast Cancer Prognostic Test – the most accurate second generation prognostic and predictive early-stage breast cancer test
Myriad Genetics’ EndoPredict Breast Cancer Prognostic Test is a gene expression test for early-stage ER-positive/HER2-negative breast cancer. It provides highly accurate prediction of early and up to 15 years risk of distant breast cancer recurrence along with treatment benefit.1-3
This second generation breast cancer test is trusted worldwide to help guide confident adjuvant chemotherapy treatment decisions for pre- and postmenopausal women. EndoPredict also provides information about the long-term risk of distant metastasis after 5 years of endocrine therapy which can guide the decision on whether extended endocrine therapy is needed.
EndoPredict gene expression assay uses molecular biology and clinical pathological factors to provide accurate prognostic insights for early-stage breast cancer
EndoPredict breast cancer test is predictive of adjuvant chemotherapy treatment benefit and prognostic of disease outcome
EndoPredict Breast Cancer Prognostic Test gene expression assay gives an individualized risk assessment to guide critical treatment decisions in early-stage breast cancer:
Can adjuvant chemotherapy be avoided?
EndoPredict breast cancer test supports confident decisions about whether adjuvant chemotherapy can be avoided.1 It gives an accurate risk assessment of distant recurrence at 10 years after 5 years of hormone therapy.
What is the absolute benefit of chemotherapy?
EndoPredict analyzes the absolute benefit of chemotherapy on risk of distant breast cancer recurrence within current treatment regimens.2
Can endocrine therapy be avoided after five years?
EndoPredict helps to decide if extended endocrine therapy for breast cancer can be avoided.3 It is the only gene expression assay that provides late distant recurrence risk up to 15 years.
More prognostic power than other breast cancer tests4,5
EndoPredict combines information about tumor size and nodal status with a gene expression signature that includes genes that predict both early and late breast cancer metastasis. This improves the prognostic power of EndoPredict compared with classical prognostic factors and first generation breast cancer tests.4-6
The higher the Likelihood (x2), the greater the prognostic power
The Likelihood (x2) is a statistical tool used to evaluate the accuracy of an algorithm and therefore the prognostic power of a test by comparing predicted outcomes with actual events. Results are independent of test cut-off values.
Want to know more?
If you are a patient, please talk to your doctor to find out if the EndoPredict breast cancer test is beneficial for you or visit our patient homepage.
If you are a clinician, learn more about the superior prognostic and predictive performance of EndoPredict for early-stage ER-positive/HER2-negative breast cancer.
Trusted worldwide for adjuvant chemotherapy and endocrine therapy treatment planning
Validated in five prospective-retrospective studies with more than 3,500 patients.1-7 First results of a prospective randomized controlled trial (UNIRAD) providing level of evidence (LoE1A) were released at SABCS 2021.8 The first results of an ongoing prospective French registry (SiMoSein) observational study with more than 4,700 patients included by now was presented at ESMO 2021.9
Recommended in many international and national guidelines, including ASCO, NCCN, AJCC, ESMO, St. Gallen, EGTM, AGO, HAS, NICE, SEOM, AIOM, CACA-CBCS, CcO.
Choose EndoPredict for fast, easy, accurate results for every patient
The EndoPredict Breast Cancer Prognosis Test is a CE-marked in vitro diagnostic (IVD) device. It can be performed in local molecular pathology laboratories.
Results are available within a few days.
Accurate – EndoPredict is a second generation test which combines clinical and molecular factors for enhanced prognostic performance, supporting accurate decisions.1
Clinically validated – EndoPredict is clinically validated across more than 3,500 pre- and postmenopausal women1-4,6,7,10 and provides with its latest results LoE 1A.8
Trusted worldwide – EndoPredict is recommended in many international and national guidelines, including ASCO, NCCN, AJCC, ESMO, St. Gallen, EGMT, AGO, HAS, NICE, SEOM, AIOM, CACA-CBS, CcO.